Gilead Sciences (GILD) investor relations material

Deal rationale and strategic fit

• Acquisitions of Tubulis, Ouro, and Arcellx align with strategic priorities in oncology, inflammation, and virology, aiming to strengthen and diversify the pipeline for long-term growth.

• Tubulis brings a next-generation ADC platform and a promising ovarian cancer asset, with broad potential across multiple tumor types.

• Ouro accelerates entry into immune-mediated diseases, focusing on B cell-driven orphan indications and autoimmune diseases.

• Full ownership of Arcellx consolidates a best-in-disease BCMA cell therapy for multiple myeloma, leveraging end-to-end CAR T expertise.

• Builds on prior collaborations and disciplined M&A, with only high-quality science and assets meeting strict acquisition criteria.

Financial terms and conditions

• Tubulis acquisition valued at $3.15 billion upfront, plus up to $1.85 billion in milestone payments.

• Ouro acquisition includes a $1.675 billion upfront payment, split with Galapagos.

• Arcellx deal values the company at $7.8 billion implied equity value ($7.1 billion net of existing stake), eliminating cost-sharing, royalties, and up to $1.5 billion in milestone payments.

• Deals funded with cash, $5 billion in short-term loans to be repaid by end of 2026, and senior unsecured notes, keeping long-term debt at ~$24 billion.

• No significant increase in 2026 operating expenses expected; R&D as a percentage of revenue to remain below 20%.

Synergies and expected cost savings

• Full ownership of Arcellx enables streamlined decision-making, unified commercial teams, and elimination of duplicative costs.

• Integration of Tubulis’ and Ouro’s platforms with internal capabilities expected to drive innovation and operational efficiency.

• Munich site to serve as a hub for ADC research and innovation.

• Shared development expenses with Galapagos for Ouro help manage R&D costs.

• Integration expected to be manageable within disciplined operating expense framework; Tubulis and Ouro modestly dilutive near term, Arcellx modestly dilutive in 2026–2027, accretive thereafter.